Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 197 Results

Intervention Indication Therapeutic Area Year Actions
Teclistamab with daratumumab for previously treated relapsed or refractory multiple myeloma Daratumumab (Darzalex; JNJ-54767414) , Teclistamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Teduglutide for short bowel syndrome in infants Teduglutide Short bowel syndrome Gastroenterology 2022 View  |  Download
Teplizumab for the delay of clinical type-1 diabetes in at-risk patients aged 8 years and over Teplizumab (PRV-031; MGA031) Type 1 diabetes Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Tiragolumab with atezolizumab for previously untreated non-small cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Tiratricol for treating monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome) Tiratricol Monocarboxylate transporter 8 deficiency (Allan-Herndon-Dudley syndrome) Genetic Disorders , Neurology 2022 View  |  Download
Tirzepatide for treating obese or overweight adults Tirzepatide (LY3298176) Obesity Cardiovascular System , Ear Nose and Throat (ENT) 2022 View  |  Download
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma Tislelizumab (BGB-A317; BGBA-317) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer Cisplatin (Platinol) , Paclitaxel (Taxol; paclitaxel albumin) , Tislelizumab (BGB-A317; BGBA-317) Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously
untreated advanced oesophageal squamous cell
Tislelizumab (BGB-A317; BGBA-317) Oesophageal squamous cell carcinoma Gastrointestinal Cancer 2022 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications